Scynexis Operating Margin from 2010 to 2024
| SCYX Stock | USD 1.28 0.04 3.03% |
Check Scynexis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scynexis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 493.9 K, Interest Expense of 2 M or Selling General Administrative of 21.9 M, as well as many indicators such as Price To Sales Ratio of 0.72, Dividend Yield of 0.0 or PTB Ratio of 2.66. Scynexis financial statements analysis is a perfect complement when working with Scynexis Valuation or Volatility modules.
Scynexis | Operating Margin |
Latest Scynexis' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Scynexis over the last few years. It is Scynexis' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Scynexis' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (15.64) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Scynexis Operating Margin Regression Statistics
| Arithmetic Mean | (58.70) | |
| Coefficient Of Variation | (182.27) | |
| Mean Deviation | 73.13 | |
| Median | (4.62) | |
| Standard Deviation | 106.98 | |
| Sample Variance | 11,445 | |
| Range | 405 | |
| R-Value | (0.1) | |
| Mean Square Error | 12,205 | |
| R-Squared | 0.01 | |
| Significance | 0.73 | |
| Slope | (2.36) | |
| Total Sum of Squares | 160,232 |
Scynexis Operating Margin History
About Scynexis Financial Statements
Scynexis investors use historical fundamental indicators, such as Scynexis' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Scynexis. Please read more on our technical analysis and fundamental analysis pages.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Scynexis operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Scynexis Stock Analysis
When running Scynexis' price analysis, check to measure Scynexis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scynexis is operating at the current time. Most of Scynexis' value examination focuses on studying past and present price action to predict the probability of Scynexis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scynexis' price. Additionally, you may evaluate how the addition of Scynexis to your portfolios can decrease your overall portfolio volatility.